Tumor‐liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof‐of‐concept study

Background Preoperative prediction of the epidermal growth factor receptor (EGFR) status in non‐small‐cell lung cancer (NSCLC) patients with liver metastasis (LM) may have potential clinical values for assisting in treatment decision‐making. Purpose To explore the value of tumor‐liver interface (TLI)‐based magnetic resonance imaging (MRI) radiomics for detecting the EGFR mutation in NSCLC patients with LM. Methods This retrospective study included 123 and 44 patients from hospital 1 (between Feb. 2018 and Dec. 2021) and hospital 2 (between Nov. 2015 and Aug. 2022), respectively. The patients received contrast‐enhanced T1‐weighted (CET1) and T2‐weighted (T2W) liver MRI scans before treatment. Radiomics features were extracted from MRI images of TLI and the whole tumor region, separately. The least absolute shrinkage and selection operator (LASSO) regression was used to screen the features and establish radiomics signatures (RSs) based on TLI (RS‐TLI) and the whole tumor (RS‐W). The RSs were evaluated by the receiver operating characteristic (ROC) curve analysis. Results A total of 5 and 6 features were identified highly correlated with the EGFR mutation status from TLI and the whole tumor, respectively. The RS‐TLI showed better prediction performance than RS‐W in the training (AUCs, RS‐TLI vs. RS‐W, 0.842 vs. 0.797), internal validation (AUCs, RS‐TLI vs. RS‐W, 0.771 vs. 0.676) and external validation (AUCs, RS‐TLI vs. RS‐W, 0.733 vs. 0.679) cohort. Conclusion Our study demonstrated that TLI‐based radiomics can improve prediction performance of the EGFR mutation in lung cancer patients with LM. The established multi‐parametric MRI radiomics models may be used as new markers that can potentially assist in personalized treatment planning.